Text Size

Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Bayside Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00164060
First received: September 13, 2005
Last updated: June 6, 2007
Last verified: September 2005
History of Changes
  Purpose

The purpose of this study is to examine the effect of GB virus C (GBV-C) on the natural history of chronic hepatitis C virus (HCV) infection in subjects co-infected with HIV and HCV. The other aspect of the study is to assess the effect of GBV-C on the severity of liver disease due to chronic hepatitis C in subjects co-infected with HIV and HCV. This will be done by determining the point prevalence of co-infection retrospectively then following that cohort prospectively. In addition, further individuals will be recruited in a prospective manner.


Condition
Hepatitis C
HIV Infections

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Bayside Health:

Estimated Enrollment: 200
Study Start Date: February 2004
Estimated Study Completion Date: May 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Sera available and appropriate for testing, including serial sera over a period of time (retrospective analysis)
  2. HIV serology positive.
  3. Unequivocal HCV antibody positive or HCV RNA positive.

Exclusion Criteria:

  1. Those without sera available.
  2. Those unwilling to give informed consent.
  3. Persons with hepatitis B virus infection, as defined by the presence of hepatitis B surface antigen and/or hepatitis B virus DNA positive.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00164060

Contacts
Contact: Mark D Berzsenyi, MBBS 0417 574 015 m.berzsenyi@alfred.org.au

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3181
Contact: Mark D Berzsenyi, MBBS     0417 574 015     m.berzsenyi@alfred.org.au    
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: Mark D Berzsenyi, MBBS Alfred Hospital/Bayside Health
Study Director: Stuart R Roberts, MBBS Alfred Hospital/Bayside Health
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00164060     History of Changes
Other Study ID Numbers: 35/04
Study First Received: September 13, 2005
Last Updated: June 6, 2007
Health Authority: Australia: Human Research Ethics Committee

Keywords provided by Bayside Health:
HCV
HIV co-infection

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Hepatitis
Hepatitis A
Hepatitis C
Immunologic Deficiency Syndromes
Virus Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
 Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
Flaviviridae Infections

ClinicalTrials.gov processed this record on March 03, 2013